National Comprehensive Cancer Network

NCCN Research & Business Resources

NCCN Oncology Research Program (ORP) Recent News

The NCCN Oncology Research Program (ORP) facilitates all phases of clinical research by identifying investigators and initiating clinical trials at NCCN Member Institutions. The NCCN ORP draws on the expertise of investigators at 26 of the world's leading cancer centers and establishes collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer. To date, the NCCN ORP has provided almost $30 million in research funding to investigators at NCCN Member Institutions. Click on a press release below to learn more about the NCCN ORP.

• NCCN Awards 3 Grants to Investigators to Study Bavituximab in Combination with Other Therapeutic Strategies in Various Cancers   (09/06/2016)
• NCCN Awards Research Grants to Eight Investigators to Support Clinical and Pre-Clinical Studies of Mirvetuximab Soravtansine in Various Cancers  (06/06/2016)
• NCCN, in Collaboration with Pfizer, Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives  (02/22/2016)
• NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies  (02/09/2016)
• NCCN Awards Research Grants to Five Investigators to Study Effectiveness of Enzalutamide in Various Cancers  (01/13/2016)
• NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies  (01/11/2016)
• NCCN Awarded $2 Million in Research Funding from Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers  (01/06/2016)

NCCN Oncology Research Program (ORP) News Archive

Please select a year to view our archived press releases:

2016     2015     2014     2013     2012     2011     2010     2009     2008     2007     2006     2005     2003     2002    

For questions about NCCN or for interview information, please contact Jennifer Tredwell 215.690.0274.